Irofulven Solid

Setmelanotide

Setmelanotide;920014-72-8;UNII-N7T15V1FUY;BIM-22493;RM-493;Imcivree;N7T15V1FUY;(4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide;Setmelanotide [USAN:INN];GTPL9272

920014-72-8

C49H68N18O9S2

HDHDTKMUACZDAA-PHNIDTBTSA-N

1117.31

1116.49

N7T15V1FUY

A08AA

Bulk Drug Intermediates

494.76

3.0807

MC4R (melanocortin-4 receptor) agonist (8-amino-acid cyclic peptide)

FDA-approved (Imcivree 2020) — orphan drug for genetic obesity

A first-in-class, 8-amino-acid cyclic peptide (Ac-Arg-cyclo[Cys-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2) that acts as a selective MC4R agonist. MC4R is a key regulator of hunger, satiety, and energy expenditure in the hypothalamus. Setmelanotide restores melanocortin signaling in patients with genetic defects in the leptin-melanocortin pathway, producing significant weight loss without cardiovascular side effects.

2.1 nM

0.27 nM

DrugBank: DB11700; ChemicalBook: CAS 920014-72-8; target validation: Chen C, et al.

NCT03242581; NCT04234042; NCT05682607

Imcivree (approved 2020-11-25)

DB11700

PubChem

FDA: Imcivree (NDA 213793); NEJM: Clément K, et al. (2020) — Setmelanotide for POMC deficiency

Setmelanotide is FDA-approved as a prescription medicine (Imcivree) for rare genetic forms of obesity (POMC/LEPR deficiency, Bardet-Biedl syndrome, Alström syndrome). This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.